Vincristine (VNC) is commonly used to treat pediatric cancers, including the most prevalent childhood malignancy, acute lymphoblastic leukemia. Although clinical evidence suggests that VNC causes peripheral neuropathy in children, the degree to which pediatric chemotherapeutic regimens influence pain sensitivity throughout life remains unclear, in part because of the lack of an established animal model of chemotherapy-induced neuropathic pain during early life. Therefore, this study investigated the effects of VNC exposure between postnatal days (P) 11 and 21 on mechanical and thermal pain sensitivity in the developing rat. Low doses of VNC (15 or 30 mg/kg) failed to alter nociceptive withdrawal reflexes at any age examined compared with vehicle-injected littermate controls. Meanwhile, high dose VNC (60 mg/kg) evoked mechanical hypersensitivity in both sexes beginning at P26 that persisted until adulthood and included both static and dynamic mechanical allodynia. Hind paw withdrawal latencies to noxious heat and cold were unaffected by high doses of VNC, suggesting a selective effect of neonatal VNC on mechanical pain sensitivity. Gross and fine motor function appeared normal after VNC treatment, although a small decrease in weight gain was observed. The VNC regimen also produced a significant decrease in intraepidermal nerve fiber density in the hind paw skin by P33. Overall, the present results demonstrate that high-dose administration of VNC during the early postnatal period selectively evokes a mechanical hypersensitivity that is slow to emerge during adolescence, providing further evidence that aberrant sensory input during early life can have prolonged consequences for pain processing.
Introduction
Advances in the clinical treatment of pediatric cancers have produced a dramatic increase in survival rates. 49 For example, the 5-year survival rate for acute lymphoblastic leukemia (ALL), the most common childhood malignancy with a peak onset between ages 2 and 3 years, has increased from 60% in 1975 to ;90% today. 24, 51 Current chemotherapy regimens for ALL commonly include the vinca alkaloid derivative vincristine (VNC). 38, 56, 60 Both adult and pediatric patients receiving tubulin-binding drugs can experience symptoms of sensory and motor peripheral neuropathy including pain and paresthesia in the hands and feet, as well as a loss of deep tendon reflexes, 28, 37, 73 which often leads to dose reduction and negatively impacts the patients' quality of life.
Preclinical studies have clearly demonstrated that pain pathways are organized in a fundamentally different manner during the early postnatal period, 19, 20, 35 which influences their response to tissue or nerve injury. For example, neonatal tissue damage can evoke unique changes in nociceptive processing within both the peripheral 6, 18, 32 and central nervous systems. [39] [40] [41] 67 In addition, the effects of peripheral nerve injury in the rodent are highly age dependent, 21, 29, 45 with the onset of neuropathic pain delayed in the neonate because of a significant developmental shift in spinal neuroimmune signaling toward a more proinflammatory phenotype during adolescence. 4, 43 Although clinical evidence supports a link between early life VNC exposure and pain hypersensitivity, the degree to which the severity of pain resulting from chemotherapy-induced peripheral neuropathy (CIPN) changes with age remains unclear. Retrospective studies include a wide range of ages at diagnosis and variations in the chosen chemotherapy agents and cumulative dosage, making it difficult to rigorously assess the effects of VNC on nociceptive processing at specific ages. Meanwhile, to our knowledge, long-term prospective studies using quantitative sensory testing approaches 78 to longitudinally measure nociceptive sensitivity in pediatric cancer survivors during adolescence or adulthood have yet to be undertaken. An animal model could yield valuable insight into the consequences of pediatric chemotherapeutic regimens for pain sensitivity throughout life. Although CIPN models have been well established in adult rodents, 1, 3, 46, 72 the known developmental changes in pain circuits make it difficult to extrapolate the previous findings to the pediatric population.
Therefore, this study investigated the effects of early life exposure to VNC on mechanical and thermal pain sensitivity in the developing rat, with the goal of establishing a preclinical model of pediatric CIPN. Our results demonstrate that VNC Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
administration during the early postnatal period evokes a selective increase in mechanical pain sensitivity that persists into adulthood. This work lays a foundation for the future exploration of the neurobiological mechanisms underlying CIPN in children and adolescents.
Methods

Subjects
Male and female Sprague Dawley rats (n 5 108; Harlan, Indianapolis, IN) were used in this study. Animals were randomly assigned to one of 2 groups: vehicle (n 5 54) or VNC (n 5 54). During treatment, animals were weighed before each injection and then once per week after treatment ended. Behavioral assays were performed on separate days to avoid stress induced by multiple tests, with a minimum of 24 hours between assays in a given animal. All rats underwent a combination of tests for mechanical and thermal sensitivity as well as motor function, although an individual animal was not subjected to all 7 behavioral assays (von Frey hairs, paintbrush, pinprick, Hargreaves test; cold plantar assay, rotarod, and foot fault test; see below) to again minimize the level of stress induced over the course of postnatal development. All experiments adhered to animal welfare guidelines established by the University of Cincinnati Institutional Animal Care and Use Committee.
Drug administration
Preliminary dose-response studies consisted of 9 total intraperitoneal injections of VNC (15, 30, 45 , or 60 mg/kg dissolved in sterile saline; Tocris) with a 4-day on, 2-day off, and 5-day on schedule starting on postnatal day (P)11. Because daily administration of 45 or 60 mg/kg VNC led to death after the third consecutive dose, we modified the dosing schedule to consist of 5 total injections of 60 mg/kg VNC on P11, 13, 17, 19, and 21. 3, 72 Although drawing exact parallels between the age of rats and humans is inherently difficult, previous work has estimated the neurodevelopmental stage of a P7 rat as roughly equivalent to that of a human born at full term. 13 P11 was chosen as a starting point in this study to (1) better reflect the clinical scenario in which VNC is most commonly administered to children between the ages of 2 and 3 rather than to newborns 51 and (2) facilitate the comparison of our findings with those of previous studies of infant neuropathic pain which used mechanical trauma to the peripheral nerve at P10. 43 In addition, the duration of VNC treatment may be relevant to the clinical observation that patients with ALL can receive VNC at varying intervals over a period of several years. 49 Littermates injected with equivalent volumes of sterile saline served as a control group.
Behavioral testing
Response to mechanical stimuli
Mechanical reflex withdrawal thresholds were measured before each injection, and then at weekly intervals until P54, by an investigator blinded to treatment group. Briefly, rats (P11-P47) were lightly restrained on a flat surface and calibrated von Frey hair monofilaments were applied to the dorsal hind paw, 71 whereas at P54, rats were placed individually into clear acrylic containers separated by black opaque dividers and the von Frey hair filaments applied to the plantar surface of the hind paw. Mechanical withdrawal thresholds were measured in all subjects according to the Simplified Up and Down method, 8 with subsets of these rats undergoing additional behavioral tests of mechanical, heat, and cold sensitivity. To assess dynamic mechanical allodynia, animals were first placed individually into clear acrylic containers separated by black opaque dividers and allowed to acclimate for at least 20 minutes. A paintbrush was used to stimulate the lateral plantar region of the hind paw in the heel-totoe direction. Responses were recorded on a scale of 0 to 3 and presented as an allodynia score, where 0 5 no response or occasionally walking away; 1 5 lifting the stimulated paw toward the body; 2 5 strong lateral lifting of the paw above the level of the body; and 3 5 shaking or licking the paw. 17 To obtain the average score for each animal, this test was repeated on each paw 3 times at 10-second intervals. For the pinprick test, a blunted needle was pressed against the plantar surface of the hind paw without penetration and repeated on each paw 3 times at 1-minute intervals. 17 The total number of withdrawals was counted for each rat and expressed as a percent response (based on a maximum of 6).
Response to heat stimuli
Sensitivity to noxious heat was assessed using the Hargreaves test. 25 Briefly, animals were first placed individually into clear acrylic containers separated by black opaque dividers on the glass surface of the thermal testing apparatus (Model 336; IITC/ Life Science Instruments, Woodland Hills, CA) and allowed to acclimate for at least 20 minutes. A mobile radiant heat source was directed to the midplantar surface of the hind paw at 5-minute intervals per rat, alternating paws, for a total of 6 trials. The radiant heat beam was turned off automatically by a photocell feedback sensor on paw withdrawal and the time was recorded. To avoid potential tissue damage, the cutoff time was set to 20 seconds. The mean withdrawal latency was calculated for each rat from the 6 trials. Withdrawal latencies were evaluated weekly starting at P26 until P54.
Response to cold stimuli
The cold plantar assay was used to evaluate noxious cold sensitivity 11 in a separate cohort of rats as was used in the tests for noxious heat sensitivity. Briefly, animals were first placed individually into clear acrylic containers separated by black opaque dividers that were set on top of 3/160 borosilicate glass (Stemmerich Inc, St. Louis, MO) and allowed to acclimate for 20 minutes before testing. A dry ice pellet was applied to the hind paw through the glass and the time until hind paw withdrawal was recorded at 5-minute intervals per rat, alternating paws, for a total of 6 trials, and the mean withdrawal latency was calculated. Withdrawal latencies were evaluated weekly starting at P20 until approximately 7 weeks of age.
Evaluation of gross motor function
Animals were placed on an accelerating rotarod treadmill set at a constant speed (4 r.p.m.). The rod was then accelerated from a rate of 4 to 40 r.p.m. over a 10-minute period. The animal's performance was recorded as the latency to fall (in seconds) and evaluated weekly starting after the last injection of VNC.
Evaluation of fine motor function
The foot fault test was used for skilled locomotor assessment. 44 On P20, animals were trained to cross a horizontal ladder with irregular rung spacing (ranging from 1 to 2 cm) from a neutral starting cage to reach their home cage. Testing consisted of 2 trials per animal and was performed weekly starting on P21 until P37. Two independent experimenters blinded to the treatment group rated each step on a 7-category scale based on the position and accuracy, as well as errors that occurred in paw placement, according to the following scoring criteria: 0 5 total miss; 1 5 deep slip; 2 5 slight slip; 3 5 replacement; 4 5 correction; 5 5 partial placement; and 6 5 correct placement. The scores from the 2 experimenters were then averaged and presented as percent accuracy.
Immunohistochemistry
At P25 and P33, animals were deeply anesthetized with sodium pentobarbital and transcardially perfused with 0.1M phosphatebuffered saline (PBS). The skin from the plantar surface of the hind paw was removed and placed in 4% paraformaldehyde (PFA) for 4 hours, then transferred to 20% sucrose overnight at 4˚C. Tissue was embedded in Tissue Freezing Medium (General Data Healthcare, Cincinnati, OH), sectioned at 40 mm using a cryostat (Leica) and processed as free-floating sections. After a 1-hour incubation in blocking solution (0.1M PBS containing 5% normal donkey serum/0.3% Triton X-100) at room temperature (RT), liquid was decanted and sections were incubated overnight at RT with the primary antibodies: PGP9.5 (rabbit, 1:500; Dako) and collagen IV (goat, 1:500; Southern Biotech). The primary antibody was then decanted and sections were washed 3 times for 30 minutes each in wash buffer consisting of PBS 1 0.3% Triton X-100. After the wash buffer was removed, the secondary antibodies donkey anti-rabbit Alexa 488 (1:500) and donkey anti-goat Alexa 594 (1:500; Jackson Immunoresearch) were added for 30 minutes at RT. After incubation with the secondary antibodies, the tissue was placed in wash buffer 3 times for 30 minutes each then mounted onto slides, coverslipped, and stored at 4˚C until imaging.
Quantification of intraepidermal nerve fibers
For intraepidermal nerve fiber (IENF) quantification, 3 plantar skin sections were selected per animal and 4 fields of view per section were chosen at random by an experimenter blinded to the treatment group. Images were obtained using a Zeiss LSM 710 confocal microscope equipped with argon and helium-neon lasers applying a 320 objective and captured as z-stacks of confocal optical sections at a thickness of 1 mm. Intraepidermal nerve fibers that crossed the collagen IV-stained dermal/ epidermal junction into the epidermis were counted (as the number of fibers per square millimeter of epidermis; IENF per square millimeter), and fibers that branched after crossing the basement membrane were recorded as a single fiber. Langerhans cells (LCs) that showed PGP9.5 immunoreactivity were counted if the cell body was visible. For each section, a mean IENF density and LC count was calculated from the 4 fields of view by 2 independent experimenters blinded to treatment group, and the results across experimenters were then averaged. For each experimental group, 4 to 6 rats were analyzed in this manner.
Statistical analysis
Behavioral data and IENF counts were analyzed using 2-way analysis of variance with Holm-Sidak post hoc tests (Prism; GraphPad Software, La Jolla, CA). Langerhans cell counts were compared between groups using the unpaired Student's t test. For all tests, the significance level was set at P , 0.05. n refers to the number of rats in a given group unless otherwise stated. All data are reported as mean 6 SEM.
Results
Toxicity of vincristine administration in the developing rat
Beginning at postnatal day (P) 11, rats were injected intraperitoneally with VNC (15, 30, 45, or 60 mg/kg) or vehicle with a 4 dayon, 2 day-off, 5 day-on schedule (see Methods). The daily administration of VNC at 45 or 60 mg/kg routinely led to death of the animal after the third injection (data not shown). Therefore, to explore the effects of high VNC doses on sensorimotor function in the developing rat, we modified the dosing protocol such that VNC was administered at 60 mg/kg 5 times between P11 and P21 (see Methods). At this dose, VNC caused a slight, but significant, decrease in the rate of weight gain in both males (F (8,433) 5 11.03, P , 0.0001, n 5 18-27; Fig. 1A ) and females (F (8,451) 5 7.40, P , 0.0001, n 5 14-27; Fig. 1B ) beginning at 3 weeks of age. Nonetheless, weight loss was never observed and the animals were judged to be in good overall health. In support of this notion, VNC administration (60 mg/kg) had no effect on gross motor function at any time point examined, as there were no www.painjournalonline.com 1649 differences in latency to fall on the rotarod test between VNCtreated rats and vehicle-treated littermates (P 5 0.82; Fig. 2A ). Assessment of fine motor skills was also performed weekly using the foot fault test (see Methods). The high dose of VNC had no impact on foot fault accuracy scores compared with vehicletreated controls (P 5 0.78; Fig. 2B ).
Vincristine administration during early life evokes delayed mechanical pain hypersensitivity
Mechanical withdrawal thresholds were measured at various postnatal ages using von Frey hair filaments after the administration of VNC or vehicle solution between P11 and P21 (see above). As described previously, 29, 66 mechanical thresholds steadily increased with age in males (F (10, Meanwhile, early life exposure to VNC at 60 mg/kg resulted in hypersensitivity to mechanical stimuli that emerged after the completion of the VNC regimen in both males (F (10,493) 5 3.42, P 5 0.0002, n 5 18-27 in each group; Fig. 3A ) and females (F (10,457) 5 6.35, P , 0.0001, n 5 14-27; Fig. 3B ), as VNCtreated animals exhibited a significant decrease in mechanical withdrawal thresholds (;35%) beginning on P26 (ie, 5 days after the final VNC injection) compared with vehicle-treated littermates (Fig. 3A, B) . This persisted throughout the testing period, with mechanical withdrawal thresholds in the VNC groups remaining significantly lower than the vehicle groups at P54. Given that VNC evoked mechanical hypersensitivity with a similar onset and duration in males and females, data from both sexes were pooled for subsequent behavioral analyses.
To investigate the degree to which VNC during the early postnatal period induces dynamic mechanical allodynia in the developing rat, the prevalence of hind paw withdrawals in response to innocuous brush was examined at multiple ages between P20 and P33. These time points were chosen to span the age at which static mechanical allodynia emerged (as measured by the administration of von Frey hairs). Importantly, VNC treatment significantly increased allodynia scores in response to a paintbrush stimulus (F (1,134) 5 8.32, P 5 0.0046, n 5 19-26 in each group), which was most evident at P26 (P 5 0.0038; Holm-Sidak posttest for multiple comparisons; Fig. 4A ). In addition, the frequency of hind paw withdrawal to pinprick stimuli was significantly elevated by VNC exposure (F (1,97) 5 12.00, P 5 0.0008, n 5 13-23; Fig. 4B ), suggesting that VNC treatment during early life also significantly increases the sensitivity to noxious mechanical stimuli.
Early vincristine treatment does not alter sensitivity to noxious thermal stimuli
Sensitivity to noxious radiant heat was examined weekly between P26 and P54 in rats treated with 60 mg/kg VNC (or vehicle), corresponding to a period during which a clear hypersensitivity to mechanical stimulation was observed (Figs. 3 and 4) . There was no significant effect of neonatal VNC administration on mean withdrawal latencies to noxious heat at any age examined (F (1, 145) 5 0.06, P 5 0.81, n 5 16 in each group; Fig. 5A ). Similarly, VNC treatment had no effect on the withdrawal latencies in response to noxious cold stimuli at any time point (F (1,238) 5 0.01, P 5 0.92, n 5 25; Fig. 5B ), suggesting that early life VNC exposure selectively increases mechanical pain sensitivity in the developing rat.
Loss of intraepidermal nerve fibers after vincristine treatment during early life
Previous studies in both humans and rats have demonstrated that VNC-and paclitaxel-induced painful peripheral neuropathies are accompanied by a reduction of IENF density corresponding to the onset of mechanical hypersensitivity. 5, 9, 10, 47, 57 Based on these reports, we next sought to determine whether the onset of mechanical allodynia was associated with changes in IENF innervation in the hind paw skin. Vincristine treatment caused a statistically significant reduction of IENF density (F (1,56) 5 5.616, P 5 0.021, n 5 12-18 sections from 4 to 6 rats in each group; Fig.  6A-C) . Although there was no difference in the number of IENFs per square millimeter of the epidermal border between treatment groups at P25 (P 5 0.607, Holm-Sidak posttest), VNC-treated rats exhibited significantly lower IENF counts relative to controls at P33 (P 5 0.047, Holm-Sidak posttest; Fig. 6C, right) . At antibody dilutions optimized for visualizing IENFs, PGP9.5 immunoreactivity www.painjournalonline.comwas also observed in LCs (Fig. 6B) , which are the resident immune cells of the skin. 2, 30, 64 As previously reported in the adult rat, 57 the reduction in IENF density after VNC treatment was accompanied by an increase in the number of PGP9.5-positive LCs (P 5 0.017, unpaired t test, n 5 12 sections from 4 rats in each group; Fig 6D) .
Discussion
The major goal of this study was to establish the first preclinical model of pediatric chemotherapy-induced neuropathic pain resulting from the administration of vinca alkaloid derivatives during early life. The results clearly demonstrate that neonatal VNC exposure evokes mechanical pain hypersensitivity that emerges after the conclusion of the treatment, persists into adulthood, and includes enhanced responses to both static and dynamic mechanical stimuli without accompanying changes in the sensitivity to noxious thermal stimulation or motor function.
In humans, symptoms of VNC-induced peripheral neuropathy are often persistent and can sometimes worsen after the termination of chemotherapy or even emerge after drug withdrawal. 48, 50 Interestingly, the mechanical hypersensitivity observed after VNC administration in the neonatal rat (as measured using von Frey hairs) failed to completely resolve during the period examined and emerged with a delay (;5 days) relative to the cessation of the VNC regimen (Fig. 3) . The increased responsiveness to a dynamic, innocuous mechanical stimulus (ie paintbrush; Fig. 4A ) and a punctate, noxious mechanical stimulus (ie, pinprick; Fig. 4B ) also appeared after the termination of the VNC treatment, with a slightly longer delay in onset observed for the hypersensitivity to pinprick. Meanwhile, previous studies of VNC-induced CIPN in adult rats have reported an earlier onset of mechanical allodynia (ie during the second week of treatment) even at lower doses (50 mg/kg 72 ) than used here, although the magnitude of the mechanical hypersensitivity was similar. 1, 3, 46, 62, 63 Importantly, recent preclinical work has clearly shown that peripheral nerve damage occurring before 3 weeks of age evokes neuropathic pain with a significant delay in onset relative to adult nerve injury, 14, 29, 66 which has been ascribed to a shift from an anti-inflammatory to proinflammatory cytokine profile within the CNS which occurs during adolescence. 43 Interestingly, this delay appears to be unique to neuropathic pain, as neonatal rats exhibit robust inflammatory pain from the first days of life after the intraplantar injection of carrageenan or complete Freund's adjuvant. 42, 70 Nonetheless, it should be noted that unlike models involving a discrete physical injury to the peripheral nerve, the precise time point at which the neonatal VNC administration causes axonal trauma is difficult to ascertain. Although we first observed a reduction in IENF density at P33 (Fig. 6) , it is possible that the fibers entered an early phase of degeneration well before this age. Future immunohistochemical or molecular analyses of neuronal stress markers in the DRG, 63 or electrophysiological measurements of axonal conduction along primary afferent fibers, 62, 75 are needed to better pinpoint the onset of axonal dysfunction after early life VNC exposure. In addition, given that symptoms of VNCinduced peripheral neuropathy can depend on cumulative dose, 16, 23 we cannot exclude the possibility that VNC doses greater than 60 mg/kg could result in an earlier emergence of mechanical hypersensitivity in the developing rat. Although our dosage is lower than those used in clinical practice to achieve antineoplastic activity, 53 toxicity issues prevented the examination of higher VNC doses in our rodent model during this particular stage of development.
As is the case in adults, mounting evidence points to important sex differences in the prevalence and magnitude of pediatric pain, with females often exhibiting greater pain sensitivity in both the clinical and experimental settings.
7,33,78 However, we observed no striking differences in the time course or magnitude of mechanical hypersensitivity between male and female littermates after early VNC exposure as measured by von Frey hair testing. Distinct mechanisms could nonetheless underlie CIPN-related pain after neonatal VNC administration in males versus females. Indeed, recent work demonstrates that the key neuroimmune interactions driving neuropathic pain are sexually dimorphic with microglia reportedly playing a prominent role in males but not females, 58, 59 although it should be noted that the importance of microglial activation for the induction of CIPN-induced neuropathic pain has been questioned. 77 Interestingly, the mechanisms contributing to neuropathic pain may partly depend on the extent of peripheral nerve damage, as knockout of toll-like receptor 4 signaling abolishes tactile allodynia selectively in males after spinal nerve ligation 61 but prevents hypersensitivity in both sexes after cisplatin-induced polyneuropathy. 74 In contrast to the marked mechanical hypersensitivity in the aftermath of neonatal VNC administration, withdrawal latencies to noxious heat or cold stimuli were not influenced by VNC treatment during early life. Previous work in adult rats has produced mixed findings with regards to the degree of thermal hyperalgesia and cold allodynia produced by VNC, with heat sensitivity reportedly increased, 1 decreased, 3, 63 or unchanged. 46, 72 Similarly, cold allodynia has been observed in response to VNC-induced neuropathy in some studies 3 but not others. 46, 72 In humans, sensory testing has revealed VNC-induced impairments in temperature sensation. Adults with VNC-induced neuropathy are more sensitive to noxious cold stimuli and have elevated warm detection thresholds, 16 whereas children are less likely to discern differences in temperature throughout the first year of VNC treatment when innocuous cold objects are applied to the skin. 36, 37 Unfortunately, to our knowledge, sensitivities to noxious cold or heat stimuli have not been evaluated in the pediatric population after VNC treatment. Therefore, the degree to which the neonatal rat model fully recapitulates the clinical phenotype seen after pediatric VNC exposure remains unclear. For example, although motor dysfunction and loss of deep tendon reflexes are observed clinically in pediatric VNC-induced neuropathy, 31,36,51,52,65 we did not observe alterations in either gross or fine motor skills in our experiments (Fig. 2) .
Damage to peripheral nerve endings and LC activation are implicated in chemoneuropathy and other neuropathic pain conditions such as postherpetic neuralgia, diabetic neuropathy, and type-I complex regional pain syndrome. 2, 12, 57 Vincristine administration during early life significantly decreased epidermal innervation and led to the appearance of PGP9.5-positive LCs (Fig. 6) , which have also been noted in adult rodent models of CIPN at the onset of hypersensitivity to mechanical stimuli. 10, 57 Langerhans cells represent the population of epidermal dendritic cells closely associated with IENF terminals. 22, 30, 55 As the resident immune cells of the skin, LCs are responsible for antigen presentation, cytokine production, and proinflammatory receptor expression. 2, 30, 64 Intraepidermal nerve fibers have been shown to regulate LC dynamics 30 and, in turn, LCs can regulate cutaneous innervation. 15 Although the functional significance of the potential interactions between IENFs and LCs in the context of CIPN remains unclear, it is possible that IENF loss may signal LC activation and subsequent cytokine release, resulting in the sensitization of the remaining nociceptive fibers or those in the process of degenerating. Indeed, Ad and C fibers from adult rats with CIPN exhibit increased spontaneous activity. 3, 62, 75 However, recent work demonstrates that the subtypes of primary afferent neurons whose excitability is altered by peripheral inflammation are dependent on the age at which the insult occurs. 32 In this regard, it will ultimately be important to characterize the excitability of developing sensory neurons at various time points after neonatal VNC treatment. It should also be noted that aberrant sensory input resulting from injury during the early postnatal period can have prolonged consequences for central nociceptive processing, including (but not limited to) a disruption in the balance between excitatory and inhibitory synaptic transmission and a facilitation of synaptic long-term potentiation (LTP) in the spinal dorsal horn, 40, 41 elevated spinal neuroimmune responses, 4,67 heightened opioidergic tone in the brain, 34, 35 and changes in descending inhibitory pathways. 68, 76 This highlights the need for future studies examining the effects of early life VNC exposure on the functional organization of developing pain networks within the CNS. Similarly, although mounting evidence from both rodents 20, [39] [40] [41] 54, 66, 68, 71 and humans 26, 27, 69 suggests that neonatal injuries can "prime" developing nociceptive pathways such that a subsequent injury evokes an exacerbated level of pain hypersensitivity, it remains to be determined whether neonatal VNC treatment modulates the behavioral response to an unrelated injury later in life. Finally, although this study investigated the effects of VNC administration to naive rats as a means to isolate the effects of the drug itself, it will ultimately be critical to elucidate how neonatal VNC alters pain sensitivity and nociceptive circuitry when administered in the presence of ALL or other pediatric cancers to better mimic the clinical scenario.
In conclusion, this work lays an essential foundation for future investigations into the neurobiological underpinnings of chemotherapy-induced neuropathic pain during early life.
